HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

N-(3-tetrahydrofuranyl)-6-aminopurine riboside

an A1 adenosine receptor agonist; structure in first source
Also Known As:
CVT 510; CVT-510; tecadenoson
Networked: 9 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Belardinelli, Luiz: 3 articles (06/2005 - 04/2003)
2. Prystowsky, Eric N: 2 articles (06/2005 - 09/2003)
3. Wolff, Andrew A: 2 articles (06/2005 - 09/2003)
4. Shreeniwas, Revati: 2 articles (06/2005 - 09/2003)
5. Jacobson, Kenneth A: 1 article (05/2011)
6. Müller, Christa E: 1 article (05/2011)
7. Elzein, Elfatih: 1 article (12/2008)
8. Zablocki, Jeff: 1 article (12/2008)
9. Sanoski, Cynthia A: 1 article (11/2005)
10. Peterman, Carla: 1 article (11/2005)

Related Diseases

1. Supraventricular Tachycardia
2. Atrial Fibrillation
01/01/2003 - "CVT-510 is also being explored as a potential agent for controlling the ventricular rate of atrial fibrillation and flutter."
01/01/2002 - "Phase II trialsfor atrial fibrillation commenced in December 1999 [349469], while a phase III trial for paroxysmal supraventricular tachycardia (PSVT) began in June 2001; this multicenter, randomized, double-blind, placebo-controlled trial, was to determine the safety and efficacy of CVT-510 in the conversion of PS VT to normal sinus rhythm [414190]. "
11/01/2005 - "Tecadenoson also appears to be associated with a lower incidence of atrial fibrillation following conversion of PSVT compared with the rates that have been associated with adenosine in the literature. "
07/01/2001 - "Selective stimulation of the A(1)-adenosine receptor by CVT-510 may be useful for immediate control of heart rate in atrial fibrillation/flutter and to convert paroxysmal supraventricular tachycardia to sinus rhythm, while avoiding vasodilatation mediated by the A(2)-adenosine receptor, as well as the vasodepressor and negative inotropic effects associated with beta-adrenergic receptor blockade and/or calcium channel blockers."
05/01/2011 - "Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A(1) agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A(2A) agonists) for myocardial perfusion imaging, preladenant (A(2A) antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A(3) agonists) for inflammatory diseases and cancer, respectively."
3. Tachycardia (Tachyarrhythmias)
4. Hypotension (Low Blood Pressure)
5. Parkinson Disease (Parkinson's Disease)

Related Drugs and Biologics

1. preladenant
2. CF101
3. 2- (cyclohexylmethylidenehydrazino)adenosine
4. Purinergic P1 Receptors (Adenosine Receptor)
5. Adenosine
6. Adenosine A1 Receptor Agonists
7. Adrenergic Receptors (Adrenergic Receptor)
8. Insulin (Novolin)
9. Nonesterified Fatty Acids (NEFA)
10. Calcium Channel Blockers (Blockers, Calcium Channel)

Related Therapies and Procedures

1. Therapeutics